Aratana Therapeutics, which is developing medications for cats and dogs based on therapies for humans, raised $35 million by offering 5.8 million shares, 250,000 more than anticipated, at $6, in line with the lower revised price. The company had previously filed to offer 4.3 million shares at a range of $11 to $13 before cutting the deal size Wednesday morning. Aratana Therapeutics will list on the NASDAQ under the symbol PETX. Stifel and Lazard Capital Markets acted as lead managers on the deal.
